[1] Zhang LL,Zhang HY,Lyu ML,et al.Increased expression of 78 kD glucose-regulated protein promotes cardiomyocyte apoptosis in a rat model of liver cirrhosis. Int J Clin Exp Pathol,2015,8(8):9256-9263. [2] 陈治莉,邓杨. 柔肝化纤颗粒联合普萘洛尔对肝硬化门脉高压患者血流动力学的影响. 现代中西医结合杂志,2016,25(21):2300-2302. [3] 王吉耀. 肝硬化门脉高压食管胃静脉曲张出血的防治. 实用肝脏病杂志,2013,16(3):195-197. [4] 莫翠毅,李世立. 卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度的近期疗效比较. 世界华人消化杂志,2014,22(27):4146-4150. [5] D'Amico G,Pagliaro L,Bosch J. Pharmacological treatment of portal hypertension:an evidence-based approach. Sem Liver Dis,1999,19(4):475-505. [6] 刘信,李敏. 三种不同方法预防肝硬化食管静脉曲张首次出血的疗效及安全性评价. 世界华人消化杂志,2014,22(2):253-258. [7] Abraldes JG,Albillos A,Banares R,et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial. Gastroenterology,2009,136(5):1651. [8] 李文渊,叶超. 普萘洛尔与卡维地洛治疗肝硬化门静脉高压的Meta分析.胃肠病学和肝病学杂志,2015,24(8):977-981. [9] 周荣斌,林霖. 急性上消化道出血急诊诊治流程专家共识(修订稿)的阐释. 中国全科医学,2015,18(33):4021-4024. [10] Kim JJ,Sheibani S,Park S,et al.Causes of bleeding and outcomes in patients hospitalized with upper gastrointestinal bleeding. J Clin Gastroenterol,2014,48(2):113-118. [11] Moreira J.Bleeding and coagulopathies in critical care. New Engl J Med,2014,370(9):2152-2153. [12] Lu Y,Loffroy R,Lau J Y W,et al. Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding. Bri J Surg,2014,101(1):34-50. [13] 芦永福,郜茜,王韵,等. 食管静脉曲张套扎术和口服普萘洛尔治疗肝硬化食管静脉曲张的疗效对比. 世界华人消化杂志,2013,21(26):2694-2697. [14] 张海月,王鲁文,龚作炯. 内镜套扎与普萘洛尔预防肝硬化食管静脉曲张首次出血效能的Meta分析. 实用肝脏病杂志,2013,16(5):436-438. [15] 陈志刚. 内镜下套扎术与普萘洛尔预防肝硬化食管静脉曲张破裂出血的临床观察. 内蒙古医学杂志,2016,48(7):869-870. [16] 李晶,孙东杰,王广川,等. 卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度效果的对比分析. 临床肝胆病杂志,2016,32(1):114-118. [17] 杨田,沈萍. 卡维地洛药理作用的研究进展. 心血管病学进展,2003,24(2):110-113. [18] 王晓艳,万晓龙,郭晓燕,等. 阿罗洛尔、普萘洛尔和卡维地洛对肝硬化大鼠门脉高压症的疗效比较. 西安交通大学学报(医学版),2015,36(6):730-734. [19] 胡培欣,王广川,胡锦华,等. 卡维地洛对肝硬化患者肝静脉压力梯度及门静脉系统血流动力学的影响. 中华消化病与影像杂志(电子版),2016,6(4):160-164. [20] 李文渊,叶超. 普萘洛尔与卡维地洛治疗肝硬化门静脉高压的Meta分析. 胃肠病学和肝病学杂志,2015,24(8):977-981. [21] Gao B,Zhang XM,Huang YM,et al.Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis. PLoS One,2017,12(3):e0174142. [22] Buechler C,Haberl EM,Rein-Fischboeck L,et al.A dipokines in liver cirrhosis.Int J Mol Sci,2017,18(7):1392. [23] Lee S,Kim DY.Non-invasive diagnosis of hepatitis B virus-related cirrhosis. World J Gastroenterol,2014,20(2):445-459. [24] Mokdad AA,Lopez AD,Shahraz S,et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010:a systematic analysis. BMC Med,2014,12:145. [25] Peng Y,Qi XS,Guo XZ.Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis:A systematic review and Meta-analysis of observational studies. Medicine(Baltimore),2016,95(8):e2877. [26] Li J,Hu SB,Wang LY,et al.Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis. Oncogene,2017,36(48):6725-6737. |